EPO treatment does not alter acute serum profiles of GFAP and S100B after TBI: A brief report on the Australian EPO-TBI clinical trial
Sarah C Hellewell, Alison Conquest, Lorraine Little, Shirley Valiance, Jasmin Board, Rinaldo Bellomo, David J Cooper, Maria Cristina DIG Morganti-Kossmann
JOURNAL OF CLINICAL NEUROSCIENCE | ELSEVIER SCI LTD | Published : 2020
PURPOSE: To determine the diagnostic and prognostic value of glial fibrillary acidic protein (GFAP) and S100B after traumatic brain injury (TBI) in an Erythropoietin (EPO) clinical trial and examine whether EPO therapy reduces biomarker concentrations. MATERIALS AND METHODS: Forty-four patients with moderate-to-severe TBI were enrolled to a sub-study of the EPO-TBI trial. Patients were randomized to either Epoetin alfa 40,000 IU or 1 ml sodium chloride 0.9 as subcutaneous injection within 24 h of TBI. RESULTS: GFAP and S100B were measured in serum by ELISA from D0 (within 24 h of injury, prior to EPO/vehicle administration) to D5. Biomarker concentrations were compared between injury severit..View full abstract
This work was supported by a Centre of Excellence in Traumatic Brain Injury Research (CETBIR) in Australia, Postdoctoral Fellowship (SCH) and an NHMRC Practitioner Fellowship (DJC).